ImageneBio, Inc. (IMA)
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
ImageneBio Inc
Trials need funding. See this company's dilution risk and cash position.
- Phase 1Completed
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
IK-175, IK-175 and nivolumab
Urothelial Carcinoma, Urothelial Carcinoma Bladder +19
NCT04200963Enrollment78StartDec 2019Primary CompletionJul 2023CompletionJul 2023 - Phase 1Terminated
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
PY159 Single agent dose level 1, PY159 Single agent dose level 2
Advanced Solid Tumor, Gynecologic Cancer +6
NCT04682431Enrollment127StartNov 2020Primary CompletionAug 2023CompletionAug 2023 - Phase 1Terminated
A Study of PY314 in Subjects With Advanced Solid Tumors
PY314, Combination Therapy: PY314 + Pembrolizumab
Advanced Solid Tumor, Gynecologic Cancer +7
NCT04691375Enrollment86StartOct 2020Primary CompletionAug 2023CompletionSep 2023 - Phase 1Terminated
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
IK-930, Osimertinib
Solid Tumors, Adult, Solid Tumor +6
NCT05228015Enrollment67StartJan 2022Primary CompletionAug 2024CompletionSep 2024 - Phase 1Withdrawn
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
IK-175 + nivolumab
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer +4
NCT05472506Enrollment0StartMar 2023est.Primary CompletionApr 2023est.CompletionApr 2023est. - Phase 1Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
IK-595
Solid Tumor, Adult, Colorectal Cancer +8
NCT06270082Enrollment75StartDec 2023Primary CompletionSep 2025CompletionSep 2025
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 1 | Completed | IK-175, IK-175 and nivolumab | NCT04200963 |
| Phase 1 | Terminated | PY159 Single agent dose level 1, PY159 Single agent dose level 2 | NCT04682431 |
| Phase 1 | Terminated | PY314, Combination Therapy: PY314 + Pembrolizumab | NCT04691375 |
| Phase 1 | Terminated | IK-930, Osimertinib | NCT05228015 |
| Phase 1 | Withdrawn | IK-175 + nivolumab | NCT05472506 |
| Phase 1 | Terminated | IK-595 | NCT06270082 |